LES LABORATOIRES SERVIER Products & Brands - Key Offerings and Insights

Products

Category

Product

Brand

Description

Epigenetics: Technologies and Global Markets (PHM044D)

Tibsovo (ivosidenib)		An IDH1 inhibitor is indicated for the treatment of AML and cholangiocarcinoma (bile duct cancer) worldwide, including in the U.S., E.U., Australia and China (except for cholangiocarcinoma).
Voranigo (vorasidenib)		An IDH1 and IDH2 inhibitor is indicated for the treatment of low-grade glioma (brain tumor).

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.